# Axon Enterprise, Inc. (AXON) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/AXON
## Company Profile
- Ticker: AXON
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 418.62 USD
- Market cap: 39504689979.24 USD
- Last updated: 2026-10-06
## Business Overview
Axon Enterprise is a public safety technology company best known for its TASER devices, body cameras, and cloud software for law-enforcement workflows. Its business is built around hardware plus recurring software and services.
## Why The Stock Is Moving

As of Oct 6, 2026, AXON closed up 1.65% at $418.62. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Axon has a growing global public-safety footprint. It is not a biotech or medtech company, but a public-safety technology platform.

## Business Model

The company generates revenue through devices, software subscriptions, evidence management, and related services. Investors watch product adoption, recurring software growth, and international expansion.

## Landscape Position

Axon is outside biotechnology entirely. If it appears in the database, it belongs in a broader growth-technology bucket rather than the healthcare or biotech stack.

## Future Catalysts

- Axon’s catalysts are software adoption, public-safety AI rollout, and continued demand for the body-cam and evidence-management ecosystem. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.

## Recent News
- 2026-09-16 04:43 EST — [Axon Announces Pricing of $1.0 Billion Offering of 0% Convertible Senior Notes Due 2031](https://biopharmsignal.com/news/AXON/axon-announces-pricing-of-1-0-billion-offering-of-0-convertible-senior-notes-due-53002b13) — Source: Axon Enterprise, Inc.
- 2026-09-15 11:05 EST — [Axon Announces Proposed Offering of $1.0 Billion of 0% Convertible Senior Notes](https://biopharmsignal.com/news/AXON/axon-announces-proposed-offering-of-1-0-billion-of-0-convertible-senior-notes-978f4026) — Source: Axon Enterprise, Inc.
- 2026-08-05 20:01 EST — [Axon reports Q2 2026 revenue of $904 million, up 35% year over year](https://biopharmsignal.com/news/AXON/axon-reports-q2-2026-revenue-of-904-million-up-35-year-over-year-cb48f7cd) — Source: Axon Enterprise, Inc.
- 2026-07-22 20:01 EST — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902) — Source: Axon Enterprise, Inc.
- 2026-05-06 20:01 EST — [Axon reports Q1 2026 revenue of $807 million, up 34% year over year](https://biopharmsignal.com/news/AXON/axon-reports-q1-2026-revenue-of-807-million-up-34-year-over-year) — Source: Axon Enterprise, Inc.